

## CD274

### Research Grade Avelumab

<b>Catalog No.</b>	DHJ70103A DHJ70103B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	MSB-0010718C, MSB0010682, CAS: 1537032-82-8		
<b>Description:</b>	Research Grade Avelumab is a fully human monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1, CD274) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1), resulting in an increased CD8+ T cell immune response. Avelumab belongs to the group of immune checkpoint blockade cancer therapies, with potential antibody-dependent cell-mediated cytotoxicity. It is used for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.		
<b>UniProt ID (target):</b>	Q9NZQ7		
<b>Specificity:</b>	Human PD-L1 (CD274)		
<b>Source:</b>	XtenCHO cell line		
<b>Isotype:</b>	Human IgG1 lambda		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Biologic Activity:</b>	Binds to PD-L1 and inhibits its binding to its receptor PD-1		
<b>Formulation:</b>	Sterile-filtered 0.01M PBS, pH 7.4		
<b>Endotoxin:</b>	< 0.01EU/µg by LAL analysis		
<b>Purity:</b>	> 95% as determined by SDS-PAGE		
<b>INN:</b>	Avelumab		
<b>Applications:</b>	Functional studies, ELISA		
<b>Storage &amp; Stability:</b>	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. <b>Avoid freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.